Form 4: MicroVision Executive Granted 241,000 RSUs
Insider Transaction Report
Simon Biddiscombe, Executive Vice Chair of MicroVision, received a grant of 241,000 Restricted Stock Units set to vest in October 2026.
Summary
- Simon Biddiscombe, Executive Vice Chair and Director of MicroVision, Inc. (MVIS), was granted 241,000 Restricted Stock Units (RSUs).
- The transaction date for this grant was October 1, 2025.
- These RSUs are scheduled to vest in full on October 1, 2026, contingent upon Mr. Biddiscombe's continued service to the company through the vesting date.
- Upon vesting, the RSUs will convert into shares of common stock on a unit-for-share basis without any payment required.
- Following this reported transaction, the number of beneficially owned derivative securities is 0, as RSUs are not considered beneficially owned until they vest.
Sentiment
Score: 6
Explanation: The filing reports a standard executive compensation grant, which is generally a neutral event but carries a slightly positive sentiment due to its role in executive retention and alignment of interests, despite potential future dilution.
Positives
- The RSU grant aligns the executive's long-term interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
- This form of compensation serves as an incentive for executive retention, encouraging continued service to the company.
Negatives
- The future conversion of RSUs into common stock will result in a dilutive effect on existing shareholders, increasing the total number of outstanding shares.
Risks
- The vesting of the RSUs is conditional on Simon Biddiscombe's continued service to MicroVision through October 1, 2026; if service ceases, the RSUs may be forfeited.
- The actual value realized by the executive from these RSUs depends entirely on the market price of MicroVision's common stock at the time of vesting.
Future Outlook
The 241,000 Restricted Stock Units granted to Simon Biddiscombe are scheduled to vest in full on October 1, 2026, provided he continues to provide services to MicroVision through that date.
Industry Context
The grant of Restricted Stock Units is a common and widely accepted practice in executive compensation across various industries, designed to attract, retain, and incentivize key management personnel by linking their compensation to the company's long-term performance.
Comparison to Industry Standards
- Not applicable as this filing reports a routine executive compensation grant, not operational or financial performance metrics that can be directly compared to industry benchmarks or specific competitor results.
Related Party Transactions
- The grant of 241,000 Restricted Stock Units to Simon Biddiscombe, an Executive Vice Chair and Director, constitutes a compensation transaction with a related party.
Stakeholder Impact
- Shareholders: Potential future dilution upon vesting of the RSUs.
- Executive (Simon Biddiscombe): Receives long-term incentive compensation tied to company performance and continued employment.
Next Steps
- The 241,000 Restricted Stock Units are expected to vest on October 1, 2026, converting into common stock, assuming the executive's continued service.
Key Dates
| Date | Description |
|---|---|
| 10/01/2025 | Date of RSU grant transaction to Simon Biddiscombe. |
| 10/02/2025 | Date the Form 4 was signed by the attorney-in-fact for Simon Biddiscombe. |
| 10/01/2026 | Scheduled full vesting date for the 241,000 Restricted Stock Units, contingent on continued service. |
Keywords
MicroVision, MVIS, Simon Biddiscombe, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.